Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 8:12:117-126.
doi: 10.2147/CMAR.S207934. eCollection 2020.

Validity of serum amyloid A and HMGB1 as biomarkers for early diagnosis of gastric cancer

Ali A Ghweil  1 , Heba A Osman  1 , Mohammed H Hassan  2 , Abeer Mm Sabry  3 , Reem E Mahdy  4 , Ahmed Rh Ahmed  5 , Ahmed Okasha  6 , Ashraf Khodeary  7 , Hesham H Ameen  8
Affiliations

Validity of serum amyloid A and HMGB1 as biomarkers for early diagnosis of gastric cancer

Ali A Ghweil et al. Cancer Manag Res. .

Abstract

Background and aim: Gastric carcinomais a frequent neoplasm with poor outcome, and its early detection would improve prognosis. This study was designed to evaluate the possible use of new biomarkers, namely SAA and HMGB1, for early diagnosis of gastric cancer.

Methods: A total of 100 patients presenting with gastric symptoms were included. All patients underwent upper endoscopic evaluation, histopathological diagnosis and serum CEA, SAA, and HMGB1 measurements.

Results: Patients were classed endoscopically with neoplastic, inflammatory, and normal-appearing gastric mucosa: 50, 25, and 25 patients, respectively. Histologically, half the patients had chronic gastritis and the remaining cases gastric carcinoma of diffuse (n=28) or intestinal (n=22) type. SAA at cutoff of 18.5 mg/L had the best validity to differentiate gastritis from gastric carcinoma, with AUC, sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) of 0.99, 98%, 100%, 100%, and 98%, respectively, followed by HMGB1 at cutoff of 14.5 pg/μL, with AUC, sensitivity, specificity, PPV, and NPV of 0.91, 70%, 96%, 94.6%, and 76.2%, respectively. Sensitivity, specificity, PPV, and NPV of serum CEA at cutoff of 2.9 ng/mL to differentiate gastritis from gastric carcinoma were 42%, 72%, 60%, and 55.4%, respectively, with AUC of 0.53. Nonetheless, higher serum levels of both SAA and HMGB1 reflected higher tumor grade (P=0.027 and P=0.016, respectively) and advanced tumor stage (P-OBrk-0.001 for both).

Conclusion: Serum levels of both SAA and HMGB1 could be of great value for early diagnosis of gastric carcinoma, comparable to the diagnostic role of serum CEA, which is not valid for early diagnosis of gastric cancer.

Keywords: CEA; HMGB1; SAA; early detection; gastric carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Endoscopy of chronic gastritis (A) and malignant polypoid mass (B).
Figure 2
Figure 2
Mild gastritis (A); severe gastritis (B); Helicobacter pylori organism (arrows) (C); intestinal gastric carcinoma (D); diffuse gastric carcinoma (E) and CK expression in diffuse gastric carcinoma (F). Notes: H&E- (A–E) and immunostained (F) sections; magnification 200× (A, B, E, F), 600× (C), and 400× (D).
Figure 3
Figure 3
Radiological assessments of included patients. Notes: (A) Multidetector computed tomography (MDCT) of polypoid mass at cardia; (B) axial MDCT of circumferential mass at pylorus; (C) diffuse tumor thickening in fundal region; (D) small mass in stomach body; (E) MDCT of portal-phase mass at pyloric antrum without extragastric extension.
Figure 4
Figure 4
ROC curve of SAA (A), HMBG1 (B), and CEA (C) for discrimination of gastric carcinoma from chronic gastritis.
See this image and copyright information in PMC

References

    1. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma review and considerations for future directions. Ann Surg. 2005;241(1):27–39. doi:10.1097/01.sla.0000149300.28588.23 - DOI - PMC - PubMed
    1. Matsuoka T, Yashiro M. Biomarkers of gastric cancer: current topics and future perspective. World J Gastroenterol. 2018;24(26):2818–2832. doi:10.3748/wjg.v24.i26.2818 - DOI - PMC - PubMed
    1. Necula L, Matei L, Dragu D, et al. Recent advances in gastric cancer early diagnosis. World J Gastroenterol. 2019;25(17):2029–2044. doi:10.3748/wjg.v25.i17.2029 - DOI - PMC - PubMed
    1. Sasazuki S, Inoue M, Sawada N, et al. Japan Public Health Center-Based Prospective Study Group. Plasma levels of C-reactive protein and serum amyloid A and gastric cancer in a nested case-control study: Japan Public Health Center-based prospective study. Carcinogenesis. 2010;31:712–718. doi:10.1093/carcin/bgq010 - DOI - PubMed
    1. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process–first American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735–6740. - PubMed